CD4 and ovarian cancer: Given that artesunate positively or negatively regulated miRNAs expression (21,22), we proposed the hypothesis that artesunate may down-regulate Sirt1 through miR-142 to promote Th1 differentiation from CD4+ T cells, thus enhancing its anticancer effect against ovarian cancer.